|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
CELLECTIS SA Acquires Diatos S.A.'s Vectocell(R) Technology to Accelerate Therapeutic Development Programs
10/12/2009 2:44:48 PM
Paris, October 12th, 2009 –Cellectis S.A. (Alternext: ALCLS), the French genome engineering
specialist, today announced that it has acquired the Vectocell® intracellular delivery technology1 from
Diatos SA in order to optimize the efficacy of its drug candidates.
The Vectocell® technology platform can improve the performance of a therapeutic compound by
enabling specific entry into the target cell compartment or organ in animals and humans. The
technology is based on the fusion between the therapeutic protein and an antibody-derived peptide
that facilitates passive entry into the cell. Experimental data show that this targeting technique
provokes minimal immunogenicity, and thus offers excellent safety. Vectocell®'s ability to provide
specific, targeted entry into any chosen cell type gives it a broad spectrum of applications.
Pharmaceutical companies, including Servier, have already trusted this technology.
"Vectocell® fits well with Cellectis' current molecular approaches and will slot into our portfolio
perfectly. It has immediate applications in our two highest-priority activities: research tools and
therapeutics ", commented Cellectis CEO André Choulika. « Vectocell® fused to a meganuclease will
transform it in biotherapeutics.
The acquisition of Vectocell® will enrich Cellectis' intellectual property portfolio by an additional 9
patent families.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing
and producing custom meganucleases for use in vivo genome surgery in the therapeutic, agrifood,
biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with
major players in the pharma, biotech and agribiotech industries and has over 20 collaborations with academic
research groups. To date, Cellectis has raised over €50 million in both equity operations and public financing and
is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our
website: www.cellectis.com
|
|
|
|
|
|
|
|
|
|
|